Special Issue "Alzheimer's Disease Drugs"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (15 January 2010)
Prof. Dr. Pierre Vandel
Psychiatry and Medical Psychology Department, University Hospital of Besançon, France
Phone: +33 3 81 21 86 11
Fax: +33 3 81 21 82 29
One of the main purpose of Alzheimer disease treatment is to improve cognitive abilities- such as memory and thinking and also slow progression of the disease. Despite many promising research current treatments cannot cure or halt the disease, but can offer some people modest improvement in some symptoms.
Alzheimer’s disease drugs are coming from 2 main categories: drugs to treat cognitive symptoms and drugs to treat specific behavioral disturbances that do not respond to non-pharmacological behavioral-management approaches. Prevention treatment are also of some importance.
Research into Alzheimer’s is focused on different possible treatments such as increasing the efficiency of the damaged nerve cells, preventing production and inhibiting the build-up of beta amyloid proteins, protecting nerve cells from the damaging effects of hydrogen peroxide.
If cholinestérase inhibitors are the first drugs developped, recent progress have highlited other drugs with different targets such as amyloid plaques or neurofibrillary tangles. Alzheimer’s vaccine, secretase modulators, anti-inflammatory drugs or even some antibiotics have been tested and seem to interfere with the development of amyloid plaques in the brain. Countless new treatments are in development, so more options will be available in the near future.
The purpose of this special issue is to assess the current status of AD drugs and perspective of new treatment stratégies through comprehensive reviews or original research datas.
Prof. Dr. Pierre Vandel
- alzheimer disease
- cognitive behavior disorder
- beta amyloid
- cholinesterase inhibitors
Article: Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders
Pharmaceuticals 2010, 3(8), 2387-2397; doi:10.3390/ph3082387
Received: 2 June 2010; in revised form: 21 June 2010 / Accepted: 20 July 2010 / Published: 26 July 2010| Cited by 1 | PDF Full-text (182 KB) | HTML Full-text | XML Full-text
Review: Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Pharmaceuticals 2010, 3(10), 3040-3100; doi:10.3390/ph3103040
Received: 28 May 2010; in revised form: 7 September 2010 / Accepted: 25 September 2010 / Published: 29 September 2010| Cited by 3 | PDF Full-text (524 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Last update: 4 March 2014